Anju Ghangurde’s Post

Setting the Course for Success in 2024 and 2025! 🚀 As we continue to navigate the dynamic landscape of the pharmaceutical industry, setting clear and ambitious goals is more crucial than ever. At Calcutta Overseas Corporation, we're excited to share our vision for the coming years. Our key goals for 2024 & 2025 include: - Expanding Our Reach: We aim to extend our distribution network across West Bengal and beyond, ensuring that quality medicines are accessible to more communities. - Building Stronger Partnerships: Strengthening relationships with our clients and partners will be at the forefront, driving mutual growth and success. - Entering New Markets: We are venturing into selling medicines directly to retailers and hospitals, expanding our impact on healthcare delivery. 💬 What are your top goals for 2024? We’d love to hear about the targets you’re setting and how you plan to achieve them. Let’s inspire each other to reach new heights! #BusinessGoals #PharmaceuticalIndustry #Leadership #WestBengal #BusinessGrowth #HealthcareExpansion #Networking

We are thrilled to announce a pivotal new addition to our BUNKA family: Dharmesh Kharwar, an esteemed strategist with an illustrious tenure in pharmaceutical and medical device manufacturing operations. Dharmesh joins us as a key orchestrator for our expansion efforts tailored specifically for the dynamic and intricate market of India. With an impressive dossier that boasts over a decade of leadership in process optimization, quality assurance, and regulatory compliance, Dharmesh is uniquely equipped to steer BUNKA’s strategic direction in the Indian context. His track record is saturated with the successful integration of innovative manufacturing protocols and the realization of productivity gains in complex production environments. Dharmesh's insight into the Indian market nuances and his pragmatic understanding of regulatory and compliance in India will be indispensable as we escalate the execution of our BUNKA™ Method—a methodology designed to actualize operational excellence and palpable growth for our clients. His credentials, featuring pivotal roles at leading multinational corporations and transformative work within competitive markets, underscore his capability to not just anticipate but architect the future landscape of India's medical device sector. Our BUNKA in India plan has been meticulously constructed to deliver incisive analysis and actionable solutions. With Dharmesh at the helm of this initiative, we stand at the cusp of redefining what it means to craft exceptional, safe, and robust medical devices and pharmaceuticals, made in India, for India and the world. Please join us in welcoming Dharmesh to the team. Here’s to a future stamped with innovation, quality, and strategic foresight – not just fulfilling the market demand,  but striving to set a benchmark for the industry worldwide! #TeamBUNKABuilding #BUNKAMethod #MedicalDeviceManufacturing #Pharmaceutical Manufacturing #WelcomeDharmesh #InnovateWithBUNKA #JeetoIndia

𝗠𝗮𝗻𝗸𝗶𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮 𝗦𝗽𝗶𝗻𝘀 𝗢𝗳𝗳 ₹𝟳𝟬𝟲 𝗖𝗿𝗼𝗿𝗲 𝗢𝗧𝗖 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗶𝗻𝘁𝗼 𝗦𝘂𝗯𝘀𝗶𝗱𝗶𝗮𝗿𝘆, 𝗙𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗙𝗼𝗼𝘁𝘀𝘁𝗲𝗽𝘀 𝗼𝗳 𝗣𝗲𝗲𝗿𝘀 𝗹𝗶𝗸𝗲 𝗦𝗮𝗻𝗼𝗳𝗶 𝗮𝗻𝗱 𝗖𝗶𝗽𝗹𝗮 Mankind Pharma, one of India's leading pharmaceutical companies in the OTC (over-the-counter) space, has spun off its consumer brands business into a wholly-owned subsidiary. This follows the path taken by companies like Sanofi India, Cipla, and Zydus Lifesciences, who have previously separated their consumer businesses to focus on growth and unlock value. The company’s consumer division, which includes well-known brands such as Manforce, Prega News, HealthOK, and AcneStar, generated ₹706 crore in revenue for FY24, contributing 7% to Mankind's overall revenue. In the June quarter of FY25 alone, the business posted revenue of ₹206 crore with an Ebitda margin of 19.5%. Mankind's move mirrors similar strategies by its peers. Cipla spun off its consumer healthcare division in 2015, and Zydus Lifesciences listed its subsidiary Zydus Wellness, which has seen nearly tenfold growth since its listing in 2009. The aim for Mankind is to increase the consumer business's share of total revenue to 15% in the long term by capitalizing on a focused strategy. As the company grows its consumer segment, there remains the potential for further value unlocking through possible fundraising or listing, similar to the success seen by Zydus Wellness. Investors are closely watching Mankind's next moves for expansion and brand development. #investmentbanking #equityresearch

🚀 𝐅𝐫𝐨𝐦 𝐇𝐮𝐦𝐛𝐥𝐞 𝐁𝐞𝐠𝐢𝐧𝐧𝐢𝐧𝐠𝐬 𝐭𝐨 𝐆𝐥𝐨𝐛𝐚𝐥 𝐃𝐨𝐦𝐢𝐧𝐚𝐧𝐜𝐞: 𝐓𝐡𝐞 𝐂𝐢𝐩𝐥𝐚 𝐒𝐭𝐨𝐫𝐲 🌍 Once upon a time in 1935, Dr. K.A. Hamied dreamed of affordable medicine for all. Fast forward to today, Cipla has become a healthcare giant, transforming lives across the globe. 💊✨ 🏔️ 𝑩𝒊𝒈𝒈𝒆𝒔𝒕 𝑪𝒉𝒂𝒍𝒍𝒆𝒏𝒈𝒆𝒔: Navigating the maze of global pharmaceutical regulations 🧩 Staying ahead in the race for innovation and research 🚀 Ensuring accessibility while maintaining affordability 💡 🏢 𝑪𝒖𝒓𝒓𝒆𝒏𝒕 𝑺𝒕𝒂𝒈𝒆: Cipla is not just surviving but thriving! With a valuation skyrocketing to over $10 billion, they continue to pioneer the industry. 🚀💰 👥 𝑬𝒎𝒑𝒍𝒐𝒚𝒆𝒆 𝑷𝒐𝒘𝒆𝒓: A robust team of over 25,000 dedicated professionals is driving Cipla’s mission forward, making a tangible impact in healthcare daily. 🌟 🌐 𝑮𝒍𝒐𝒃𝒂𝒍 𝑭𝒐𝒐𝒕𝒑𝒓𝒊𝒏𝒕: From their roots in India to a presence in over 80 countries, Cipla’s reach is truly global. They’re not just participating in the global market—they're leading it! 🌏🌟 𝐻𝑒𝑟𝑒’𝑠 𝑡𝑜 𝐶𝑖𝑝𝑙𝑎: 𝑎 𝑏𝑒𝑎𝑐𝑜𝑛 𝑜𝑓 ℎ𝑜𝑝𝑒, 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛, 𝑎𝑛𝑑 𝑒𝑥𝑐𝑒𝑙𝑙𝑒𝑛𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙 𝑤𝑜𝑟𝑙𝑑. 𝑇ℎ𝑒 𝑗𝑜𝑢𝑟𝑛𝑒𝑦 𝑖𝑠 𝑓𝑎𝑟 𝑓𝑟𝑜𝑚 𝑜𝑣𝑒𝑟, 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑓𝑢𝑡𝑢𝑟𝑒 𝑙𝑜𝑜𝑘𝑠 𝑏𝑟𝑖𝑔ℎ𝑡𝑒𝑟 𝑡ℎ𝑎𝑛 𝑒𝑣𝑒𝑟! 🚀🌟 #𝐻𝑒𝑎𝑙𝑡ℎ𝑐𝑎𝑟𝑒 #𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑒𝑢𝑡𝑖𝑐𝑎𝑙𝑠 #𝐶𝑖𝑝𝑙𝑎 #𝐼𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 #𝐺𝑙𝑜𝑏𝑎𝑙𝑅𝑒𝑎𝑐ℎ #𝐿𝑒𝑎𝑑𝑒𝑟𝑠ℎ𝑖𝑝 #𝐴𝑓𝑓𝑜𝑟𝑑𝑎𝑏𝑙𝑒𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 #𝑇𝑒𝑎𝑚𝐶𝑖𝑝𝑙𝑎

Piramal Pharma Ltd - Abbott 𝐃𝐞𝐚𝐥: -𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐢𝐧 𝐢𝐭𝐬𝐞𝐥𝐟 𝐓𝐡𝐞 𝐆𝐫𝐞𝐚𝐭 𝐈𝐧𝐝𝐢𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐒𝐭𝐨𝐫𝐲 👏 The Piramal-Abbott deal of 2010 stands out as a landmark transaction in the global pharmaceutical industry and a turning point for Indian pharma. This $3.72 billion acquisition by Abbott Laboratories was not just a financial milestone but a turning point in how Indian pharma positioned itself on the global stage. Ajay Piramal's visionary leadership and Abbott's strategic ambition transformed the industry landscape. 𝗧𝗵𝗲 𝗗𝗲𝗮𝗹 𝗶𝗻 𝗗𝗲𝘁𝗮𝗶𝗹 What Abbott Acquired: 1. Piramal Healthcare's domestic formulations business, comprising branded generics and a robust distribution network. Financial Structure: 1.$2.12 billion upfront and $400 million annually for four years. 2. The valuation of 30 times EBITDA (9x sales) set global benchmarks. 𝗪𝗵𝘆 𝗪𝗮𝘀 𝗧𝗵𝗶𝘀 𝗗𝗲𝗮𝗹 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆? 1.Record Valuation and Global Spotlight Valuation: Among the highest globally for a pharma company, showcasing the value of India's branded generics market. Example: Post-deal, global giants like Pfizer, Mylan, and Teva sought Indian partnerships. 2. Catalyst for India’s Pharma Industry The transaction underscored India’s strength in branded generics, inspiring confidence among investors and MNCs about Indian pharma's potential. Example: Sun Pharma’s 2014 acquisition of Ranbaxy for $4 billion 3. Abbott’s Instant Market Leadership in India Abbott became the largest pharmaceutical company in India post-deal, achieving a market share of over 7% overnight. 4. Ajay Piramal’s Strategic Vision The deal exemplified Ajay Piramal’s foresight in capitalizing on opportunities for long-term growth. Instead of clinging to a successful business, he chose to reinvest the proceeds in high-margin areas like CDMO (Contract Development and Manufacturing Organization) services, consumer healthcare, and financial services. Example: Piramal acquired Coldstream Laboratories (2015), enhancing its injectable manufacturing capabilities. The company diversified into real estate and financial services, establishing Piramal Capital and Housing Finance as a leading player in India. 5. Pioneering Focus on Consumer Healthcare The deal enabled Piramal to reallocate resources to its OTC (Over-the-Counter) business, building household brands and targeting consumer health needs. Example: Saridon: Enhanced marketing campaigns (“Sirf Ek Saridon”) ensured continued market leadership. i-Pill: Targeted campaigns on women’s health transformed it into a category-defining product. To know more on this deal - https://lnkd.in/gpdXyThV Conclusion- It catapulted Abbott to market leadership in India and enabled Piramal to diversify into high-growth sectors #IndianPharmaRevolution #PiramalAbbottDeal #VisionaryLeadership #GlobalPharma

Is India set to become the world's pharmaceutical leader? I repeatedly asked this question, and now I’m happy to see this vision come into reality. I recently came across a statement that India is set to become the world's pharmaceutical hub soon. As proud as this statement makes me, it also takes me back to the series of responsibilities it has exposed all of us working in #pharmaceuticals. It is useless not to mention how technological integration has recently become a growing parameter in #healthcare. So, what are our scopes to bring this statement to reality as a nation? → India has 741 USFDA and over 2,050 WHO-GMP-certified facilities. → Substantial investments of Rs. 1,000 crore in bulk drugs for FY25 are made to boost manufacturing capacity and supply both the domestic and international markets. → India boosts pharmaceutical R&D with a ₹4,250 crore investment focusing on urgent health challenges. → Lastly, effective government incentives and simplified regulatory processes — Government incentives like the Rs 15,000 crore PLI scheme should be encouraged more. I always say #health is a collective approach that each individual in this sector needs to adhere to. Our goal should not just be to manufacture high-end products but also to invest in potential technologies and infrastructures. Simultaneously expanding our pharmaceutical hubs will make India’s position stronger on the global map as a pharmaceutical bastion. I have upscaled and reached heights in my journey of business through learning and collaboration. As we are molding to a fast-paced digital world, why leave any collaborative opportunity unturned? I always involve myself in such conferences and meet and greets. Personally, I look forward to collaborations between universities and the industry and more investment in biotech and new drug development. Because the potential of India is endless. To add the final touches, we need some support from the government. One way to do this is by implementing policies that incentivize production levels and expedite the drug approval process. Thus, I’m way too excited to see the growth, innovations, and technology that will lead the pharma frontline. #PharmaGrowth #IndianPharmacueticalMarket

🌏 India: An Attractive Proposition for Global Pharma & Medtech’s Latest Innovations? 🧠 India's GDP and pharma market value are soaring. Moreover, as the policy environment shifts towards prioritising the domestic development of more advanced products, opportunities are opening up for MNCs - with well-planned strategies in place - to bring their latest innovations to the country. 🔍 Featuring insights from: Vikrant Shrotriya, Novo Nordisk Suresh Pattathil, AbbVie & OPPI India Girisan Kariangal, MENARINI Group Pratima Reddy, Merck Healthcare Sampada Gosavi, Astellas Pharma Shishir Agarwal, Terumo India Private Limited PIERRE PEREZ, Servier India Private Limited They discuss the positive shifts in policy, business environment improvements, and the importance of adaptability, affordability, and education in ensuring the success of innovative therapies in India. Get the full picture at: https://lnkd.in/d5NkQSEW

We always talk about the growth and all. Future prospects and exploration regarding new dimension in Indian Pharma Industry. I think we donot have the capacity to think about, How big a single brand can be. When I was working for Abbott India, That time I was listening Humira is world largest value wise product worldwide. Now as per the latest Data Merck Keytruda Injection TO is 25+ Billion dollar. This single brand is how much fold of Indian Pharma Industry. I think we should learn from MNCs as leasson and we should not talk about always the price. Abhi hame kafi kuch sikhana hai..........

JB Pharma aims to grow by 12-14% in the next 2 years. Day #61 💊JB Pharma in the news buzz.! Mumbai based JB Pharma is aiming to grow its revenue by 12-14 per cent in the next two years. 💊How do they plan to do.? The company is particularly focused on expanding its presence in the chronic medicines segment and its contract development and manufacturing organization (CDMO) business. 💊Who and all have they tied up with.? JB Pharma partners with top international players like Reckitt, P&G, J&J, and Inova to manufacture cough and cold lozenges. 💊Where are they planning to expand.? The company is planning to expand towards Europe and Brazil through tie-ups and product launches. I will provide the source of the article in the comment section below. By the way today is the 61st day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #finance #Linkedin #India